Panacea Biotec shares surged to a 52-week high of Rs 165 on September 18 buoyed by high-volume trade. Nearly one crore shares of the pharma company changed hands against a monthly average of 8 lakhs.
The sharp uptick in the stock price came after Dr Cyrus Poonawalla’s Serum Institute of India offloaded 4 lakh shares in the last trading session on September 15 at an average price of Rs 140.65.
According to data published by the NSE, the vaccine maker sold its shares in the company for the second time in the ongoing quarter after having offloaded 5 lakh shares in August at an average price of Rs 146.31.
At 12.15pm on the NSE, the Panacea Biotec stock was quoting Rs 157.90 apiece, up Rs 11.60, or 7.95 percent from the last close.
Follow our live blog for all the market action
In its results for the April-June quarter, Panacea Biotec reported a 16.21 percent YoY (year-on-year) increase in revenue from operations at Rs 129 crore. Net profit for the quarter was Rs 11 crore against a loss of Rs 56 crore reported in the same period year before. The operating losses for the quarter were recorded at Rs 10 crore against an operating loss of Rs 80 crore reported in the corresponding quarter of the previous fiscal.
Panacea Biotec is engaged in the business of pharmaceuticals and biotechnology. The company specialises in development and manufacturing of vaccines and biosimilars, apart from antibiotics, and other pharmaceutical formulations.
Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
